KEGG   PATHWAY: hmh05216
Entry
hmh05216                    Pathway                                
Name
Thyroid cancer - Hylobates moloch (silvery gibbon)
Description
Thyroid cancer is the most common endocrine malignancy and accounts for the majority of endocrine cancer- related deaths each year. More than 95% of thyroid carcinomas are derived from follicular cells. Their behavior varies from the indolent growing, well-differentiated papillary and follicular carcinomas (PTC and FTC, respectively) to the extremely aggressive undifferentiated carcinoma (UC). Somatic rearrangements of RET and TRK are almost exclusively found in PTC and may be found in early stages. The most distinctive molecular features of FTC are the prominence of aneuploidy and the high prevalence of RAS mutations and PAX8-PPAR{gamma} rearrangements. p53 seems to play a crucial role in the dedifferentiation process of thyroid carcinoma.
Class
Human Diseases; Cancer: specific types
Pathway map
hmh05216  Thyroid cancer
hmh05216

Organism
Hylobates moloch (silvery gibbon) [GN:hmh]
Gene
116461332  RET; proto-oncogene tyrosine-protein kinase receptor Ret isoform X1 [KO:K05126] [EC:2.7.10.1]
116458314  CCDC6; coiled-coil domain-containing protein 6 [KO:K09288]
116460963  NCOA4; nuclear receptor coactivator 4 isoform X1 [KO:K09289]
116467918  NTRK1; high affinity nerve growth factor receptor [KO:K03176] [EC:2.7.10.1]
116469370  TPM3; tropomyosin alpha-3 chain isoform X1 [KO:K09290]
116457894  TPR; nucleoprotein TPR isoform X1 [KO:K09291]
116467007  TFG; protein TFG isoform X1 [KO:K09292]
116466571  HRAS; GTPase HRas isoform X3 [KO:K02833]
116469568  NRAS; GTPase NRas [KO:K07828]
116472788  KRAS; GTPase KRas isoform X1 [KO:K07827]
116814428  BRAF; serine/threonine-protein kinase B-raf isoform X1 [KO:K04365] [EC:2.7.11.1]
116482295  MAP2K1; dual specificity mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
116814342  dual specificity mitogen-activated protein kinase kinase 2-like [KO:K04369] [EC:2.7.12.2]
116483548  MAP2K2; dual specificity mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
116459126  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
116470222  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
116483378  PAX8; paired box protein Pax-8 [KO:K09293]
116466751  PPARG; peroxisome proliferator-activated receptor gamma isoform X1 [KO:K08530]
116475838  RXRA; retinoic acid receptor RXR-alpha isoform X1 [KO:K08524]
116460446  RXRB; retinoic acid receptor RXR-beta isoform X1 [KO:K08525]
116472315  RXRG; retinoic acid receptor RXR-gamma isoform X2 [KO:K08526]
116459052  TP53; cellular tumor antigen p53 [KO:K04451]
116460475  CDKN1A; cyclin-dependent kinase inhibitor 1 isoform X1 [KO:K06625]
116469918  GADD45A; growth arrest and DNA damage-inducible protein GADD45 alpha [KO:K04402]
116483299  GADD45B; growth arrest and DNA damage-inducible protein GADD45 beta [KO:K04402]
116475228  GADD45G; growth arrest and DNA damage-inducible protein GADD45 gamma [KO:K04402]
116478225  BAX; apoptosis regulator BAX isoform X3 [KO:K02159]
116459971  BAK1; bcl-2 homologous antagonist/killer isoform X1 [KO:K14021]
116813623  LOW QUALITY PROTEIN: bcl-2 homologous antagonist/killer-like [KO:K14021]
116476282  DDB2; DNA damage-binding protein 2 isoform X1 [KO:K10140]
116462469  POLK; DNA polymerase kappa isoform X1 [KO:K03511] [EC:2.7.7.7]
116471429  CDH1; cadherin-1 [KO:K05689]
116473623  CTNNB1; catenin beta-1 isoform X1 [KO:K02105]
116471505  TCF7; LOW QUALITY PROTEIN: transcription factor 7 [KO:K02620]
116483590  TCF7L1; transcription factor 7-like 1 isoform X2 [KO:K04490]
116483446  TCF7L2; transcription factor 7-like 2 isoform X12 [KO:K04491]
116479176  LEF1; lymphoid enhancer-binding factor 1 isoform X1 [KO:K04492]
116813588  MYC; myc proto-oncogene protein [KO:K04377]
116469117  CCND1; G1/S-specific cyclin-D1 [KO:K04503]
Reference
  Authors
Kondo T, Ezzat S, Asa SL.
  Title
Pathogenetic mechanisms in thyroid follicular-cell neoplasia.
  Journal
Nat Rev Cancer 6:292-306 (2006)
DOI:10.1038/nrc1836
Reference
  Authors
Chiloeches A, Marais R.
  Title
Is BRAF the Achilles' Heel of thyroid cancer?
  Journal
Clin Cancer Res 12:1661-4 (2006)
DOI:10.1158/1078-0432.CCR-06-0051
Reference
  Authors
Reddi HV, McIver B, Grebe SK, Eberhardt NL
  Title
The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis.
  Journal
Endocrinology 148:932-5 (2007)
DOI:10.1210/en.2006-0926
Reference
  Authors
Santoro M, Melillo RM, Fusco A.
  Title
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.
  Journal
Eur J Endocrinol 155:645-653 (2006)
DOI:10.1530/eje.1.02289
Reference
  Authors
Pierotti MA, Greco A.
  Title
Oncogenic rearrangements of the NTRK1/NGF receptor.
  Journal
Cancer Lett 232:90-8 (2006)
DOI:10.1016/j.canlet.2005.07.043
Reference
  Authors
Sobrinho-Simoes M, Preto A, Rocha AS, Castro P, Maximo V, Fonseca E, Soares P.
  Title
Molecular pathology of well-differentiated thyroid carcinomas.
  Journal
Virchows Arch 447:787-93 (2005)
DOI:10.1007/s00428-005-0065-5
Reference
  Authors
Gimm O.
  Title
Thyroid cancer.
  Journal
Cancer Lett 163:143-56 (2001)
DOI:10.1016/S0304-3835(00)00697-2
Reference
  Authors
Williams D.
  Title
Cancer after nuclear fallout: lessons from the Chernobyl accident.
  Journal
Nat Rev Cancer 2:543-9 (2002)
DOI:10.1038/nrc845
Related
pathway
hmh03320  PPAR signaling pathway
hmh04010  MAPK signaling pathway
hmh04115  p53 signaling pathway
hmh04310  Wnt signaling pathway
hmh04520  Adherens junction
KO pathway
ko05216   
LinkDB

DBGET integrated database retrieval system